Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in <i>NRAS</i>-Mutant Melanoma Cell Lines
The Ras/MEK/ERK pathway has been the primary focus of targeted therapies in melanoma; it is aberrantly activated in almost 80% of human cutaneous melanomas (≈50% <i>BRAF</i>V600 mutations and ≈30% <i>NRAS</i> mutations). While drugs targeting the MAPK pathway have yielded suc...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/9/2012 |